Ocular adnexal lymphoid tumors.

Area of Science:

• Ophthalmology
• Hematology
• Oncology

Background:

• Ocular adnexal lymphoid tumors require updated management strategies.
• Distinguishing between Mucosa-Associated Lymphoid Tissue (MALT) and non-MALT lymphomas is crucial for treatment.
• The REAL classification system is now standard for ocular adnexal lymphomas.

Purpose of the Study:

• To review recent advances in the management of ocular adnexal lymphoid tumors.
• To highlight the prognostic and therapeutic implications of differentiating MALT from non-MALT lymphomas.
• To discuss the updated classification system for these tumors.

Main Methods:

• Literature review of recent studies on ocular adnexal lymphoid tumors.
• Analysis of treatment outcomes based on lymphoma subtype (MALT vs. non-MALT).
• Comparison of the REAL classification system with older systems.

Main Results:

• MALT lymphomas exhibit a more indolent clinical course compared to non-MALT lymphomas.
• Conservative management is feasible for conjunctival MALT lymphomas.
• Orbital MALT lymphomas have a high risk of systemic progression, necessitating radiation therapy.
• Most ocular adnexal lymphomas are B-cell in origin, though T-cell lymphomas also occur.

Conclusions:

• The distinction between MALT and non-MALT lymphomas significantly impacts management strategies for ocular adnexal tumors.
• Treatment approaches should be tailored to the specific subtype and location (conjunctiva vs. orbit).
• Radiation remains a key treatment modality for orbital lymphomas due to systemic progression risk.